The Gibbs Cancer Center & Research Institute and Spartanburg Regional Healthcare System have joined a research team organized by life sciences company GRAIL Inc. as part of a project to improve early-stage cancer detection.
The first multi-center clinical study of GRAIL is the Circulating Cell-free Genome Atlas (CCGA) study. The research is designed to help with the development of a blood test for early-stage cancer detection.
“Detecting cancer at an earlier stage when it can be cured is an ambitious goal with the potential for immeasurable benefit to society,” says Dr. Timothy Yeatman, president of Gibbs Cancer Center and the chief scientific officer of the Guardian Research Network. Gibbs Cancer Center has expanded its research work through the formation of the Guardian Research Network, which is a nationwide consortium of community health systems that work to accelerate cures for cancer.
Collaborators in the CCGA study include the Mayo Clinic, Hartford HealthCare Cancer Institute, and the Guardian Research Network. Yeatman is one of the eight members of the CCGA Scientific Advisory Board.
The CCGA study’s work will characterize the landscape of cell-free DNA profiles in people with cancer and healthy people who do not have the disease. The GRAIL’s ultra-broad and ultra-deep sequencing approach will be used.
Researchers expect the results to provider greater knowledge about the biology of cancer in its earliest stages. Also, they hope to develop models that can predict who has cancer.
“We have already begun enrolling study participants across our broad network of cancer centers and hospitals in the U.S.,” Yeatman says.